A randomised study of allogeneic transplantation with stem cells from blood or bone marrow

Bone Marrow Transplantation

Volumn 25, Issue 11, 2000, Pages 1129-1136

  Heldal, D ^a   Tjonnfjord G ^a   Brinch, L ^a   Albrechtsen, D ^a   Egeland, T ^a   Steen, R ^a   Solheim, B G ^a   Evensen, S A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Allogeneic bone marrow transplantation; Blood progenitor cells; G CSF

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CELL COUNT; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT;

EID: 0034129402     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702422     Document Type: Article

References (42)

1. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
2. Sheridan WP, Begley GC, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
3. Bensinger WI, Singer J, Appelbaum FR et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony-stimulating factor. Blood 1993; 81: 3158-3162.
4. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
5. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
6. Kessinger A, Smith DM, Strandjord SE. Allogeneic transplantation of blood-derived T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-646.
7. Russel NH, Hunter AE, Rogers S et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation (letter). Lancet 1993; 341: 1482.
8. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
9. Dreger P, Suttorp M, Haferlach T et al. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-1409.
10. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
11. Körbling M, Przepiorka D. Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
12. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
13. Azevedo WM, Aranha FJP, Gonvea JV et al. Allogeneic transplantation with blood stem cells mobilized by rh-G-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16: 647-653.
14. Gratwohl A, Hermans J, Baldomero H. Blood and marrow transplantation activity in Europe 1995. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 407-419.
15. Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
16. Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and marrow transplantation activity in Europe 1996. Bone Marrow Transplant 1998; 22: 227-240.
17. Heldal D, Brinch L, Evensen SA et al. A randomized study of allogeneic transplantation with stem cells from blood (PBPCT) or bone marrow (BMPCT). Bone Marrow Transplant 1997; 19 (Suppl. 1): 73 (Abstr. 289).
18. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicenter trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
19. Vigorito AC, Azevedo WM, Marques JFC et al. A randomised prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
20. Biaise D, Kuentz M, Fortanier C et al. Randomised trial of lenograstim-primed blood cell (BC) versus BM allogeneic transplantation: a study from the Société Française de Greffe de Moelle Osseuse. Bone Marrow Transplant 1999; 23 (Suppl. 1): 17 (Abstr. 56).
21. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a higher risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
22. Urbano-Ispizua A, Garcia-Conde S, Brunet S et al. High incidence of chronic GVHD after allogeneic peripheral blood progenitor cell transplantation from matched related donors. Blood 1996; 88 (Suppl. 1): 617a.
23. Majolino I, Saglio G, Scimè R et al. High incidence of chronic GVHD after primary peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555-560.
24. Scott MA, Gandhi MK, Jestice HK et al. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. Bone Marrow Transplant 1998; 22: 273-276.
25. Brown RA, Adkins D, Khoury H et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999; 17: 806-812.
26. Kaplan ED, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2795-2801.
28. + cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). J Hematother 1996; 5: 237-245.
29. Glucksberg H, Storb R, Fefer A et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.
30. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
31. Przepiorka D, Smith T, Folloder J et al. A controlled trial of filgrastim in allogeneic blood stem cell transplantation. Bone Marrow Transplant 1999; 23 (Suppl. 1): 82 (Abstr. 267).
32. Rosenfeld C, Collins R, Pineiro L et al. Allogeneic blood stem cell transplantation without post-transplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study. J Clin Oncol 1996; 14: 1314-1319.
33. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. Bone Marrow Transplant 1996; 18: 35-40.
34. + cell dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
35. Miflin G, Russel NH, Hutchinson RM et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9-13.
36. Blaise D, Jourdan E, Michallet M et al. Mobilisation of healthy donors with lenograstim and transplantation of HLA-geno-identical blood progenitors in 54 patients with hematological malignacies: a pilot study. Bone Marrow Transplant 1998; 22: 1153-1158.
37. Couban S, Dranitsaris G, Andreou P et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant 1998; 22: 1199-1205.
38. dim) and lymphoid subsets, and possible predictors of engraftment and GVHD. Blood 1995; 86: 2842-2848.
39. Elmaagacli AH, Beelen DW, Opalka B et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999; 94: 384-389.
40. Glass B, Uharec L, Zeis M et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood 1997; 90: 1694-1700.
41. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Blood Marrow Transplant 1997; 3: 45-49.
42. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-908.